The European Union (EU) and India have announced that they will engage together in research and innovation to develop a Next Generation Influenza Vaccine to Protect Citizens Worldwide. In total, €30 million (Rs 240 crores) has been earmarked for research and innovation actions, which aim at advancing the efficacy, safety, duration of immunity, and reactivity against an increased breadth of influenza strains. Both the EU and the Department of Biotechnology (DBT), Government of India, have committed €15 million each to fund this joint call. The EU is funding this call under its programmer for research and innovation 'Horizon 2020' (2014-2020). These joint efforts also aim to develop cost-effective and affordable influenza vaccine rapidly without compromising quality. Keeping this in mind, the participating consortia need to bring together multi-disciplinary stakeholders representing the complete value chain from Lab to Market including pre-clinical trials and vaccine developers. The call was launched on 28 August 2018 in the presence of H.E. Mr Tomasz Kozlowski, Ambassador of the European Union to India and Dr Renu Swarup, Secretary of the Department of Biotechnology (DBT).